journal article·2019-12-04Open access

Preparation, characterization and in vitro evaluation of PEGylated nanoliposomal containing etoposide on lung cancer

Fatemeh Zare Kazemabadi, Amir Heydarinasab, Azim Akbarzadeh, Mehdi Ardjmand

Abstract

Introduction and objective: Lung cancer is the most common one in terms of outbreak and mortality. Since most modern treatments have many side effects, finding an effective and alternative therapy seems necessary. The present study aimed to determine the effect of PEGylated liposomal etoposide nanoparticles on the lung cancer (A-549 and Calu6 cell lines). Materials and methods: The PEGylated liposomal etoposide nanoparticles were prepared by reverse-phase evaporation method. The particle size and zeta potential of the nanoparticles were measured by Zetasizer. The nanoparticle cytotoxicity was examined by MTT method. The vesicular drug release pattern was examined by dialysis method. The amount of loaded drug and the encapsulation efficiency (EE) was also measured and calculated. Apoptosis test was performed using flow cytometry with Annexin V kit. Results: The mean particle size, size distribution, and zeta potential of PEGylated liposomal etoposide nanoparticles were 122.5 ± 4.8 nm, 0.252 ± 0.12 and -13.7 ± 0.51 mv, respectively. The etoposide release in prepared formulations was detected to be about 15.64% after 50 hr. The cytotoxic effect of etoposide nanoparticles on lung cancer A-549 and Calu6 cell lines showed more anti-tumour activity compared to the free drug used. Conclusion: The results showed that the PEGylated liposomal nanoparticles were used as a suitable nanocarrier for etoposide injection. It was also found that the drug effect on the nanodrug formulations was higher than that of the free drug.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Lung Cancer Research Studies · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical Engineering, Science and Research Branch, Islamic Azad University

Department of Pilot Nanobiotechnology, Pasteur Institute of Iran

Department of Chemical Engineering, South Tehran Branch, Islamic Azad University

References (41)

Show source-provided references
1. 10.1016/S0076-6879(09)65013-810.1016/S0076-6879(09)65013-8 ↗
2. 10.2174/15672011179366360610.2174/156720111793663606 ↗
3. 10.1016/S1470-2045(10)70087-510.1016/S1470-2045(10)70087-5 ↗
4. 10.1016/j.canlet.2006.11.00510.1016/j.canlet.2006.11.005 ↗
5. 10.1201/978142002799010.1201/9781420027990 ↗
6. 10.3390/ijerph907244410.3390/ijerph9072444 ↗
7. 10.1002/rmv.182510.1002/rmv.1825 ↗
8. 10.4314/tjpr.v14i8.1410.4314/tjpr.v14i8.14 ↗
9. 10.1016/B978-0-12-374934-5.00042-810.1016/B978-0-12-374934-5.00042-8 ↗
10. 10.1155/2012/51641710.1155/2012/516417 ↗
11. 10.3906/sag-1412-6710.3906/sag-1412-67 ↗
12. 10.1016/S0065-2571(00)00013-310.1016/S0065-2571(00)00013-3 ↗
13. Izadi M, Ebrahimi Shahemabadi H, Kanaani L. Investigation of characteristics of loaded carboplatin on the liposomal nanoparticles on the cell carcinoma of the human brain c6. Adv Biores. 2016;7:113–118.
14. 10.1111/cbdd.1286910.1111/cbdd.12869 ↗
15. 10.3390/molecules2304090710.3390/molecules23040907 ↗
16. 10.1016/j.urolonc.2007.03.01510.1016/j.urolonc.2007.03.015 ↗
17. 10.1053/j.seminoncol.2004.08.00110.1053/j.seminoncol.2004.08.001 ↗
18. 10.1111/cbdd.1278610.1111/cbdd.12786 ↗
19. 10.3389/fphar.2015.0028610.3389/fphar.2015.00286 ↗
20. 10.1007/s12291-016-0596-310.1007/s12291-016-0596-3 ↗
21. 10.31557/APJCP.2019.20.1.30310.31557/APJCP.2019.20.1.303 ↗
22. Guideline IH. Validation of analytical procedures: text and methodology Q2 (R1). Geneva (Switzerland): ICH; 2005, Vol. 10, p. 11–12.
23. 10.22270/jddt.v9i3.286810.22270/jddt.v9i3.2868 ↗
24. 10.2147/IJN.S803010.2147/IJN.S8030 ↗
25. Esmaeili Govarchin Ghaleh H, Zarei L, Mansori Motlagh B, et al. Using CuO nanoparticles and hyperthermia in radiotherapy of MCF-7 cell line: synergistic effect in cancer therapy. Int J Nanomedicine. 2019;47:1396–1403.
26. 10.1039/C6NR03525F10.1039/C6NR03525F ↗
27. 10.1016/j.addr.2012.09.02210.1016/j.addr.2012.09.022 ↗
28. 10.1016/j.colsurfb.2011.10.05110.1016/j.colsurfb.2011.10.051 ↗
29. 10.1016/S0378-5173(02)00703-210.1016/S0378-5173(02)00703-2 ↗
30. 10.3322/caac.2010210.3322/caac.20102 ↗
31. 10.1007/s11095-010-0154-210.1007/s11095-010-0154-2 ↗
32. 10.3797/scipharm.0806-0810.3797/scipharm.0806-08 ↗
33. Dua JS, Rana AC, Bhandari AK. Liposome: methods of preparation and applications. Int J Pharm Stud Res. 2012;3:14–20.
34. 10.1016/j.ijpharm.2008.12.03010.1016/j.ijpharm.2008.12.030 ↗
35. 10.3109/03639045.2010.54541410.3109/03639045.2010.545414 ↗
36. 10.4314/tjpr.v14i2.110.4314/tjpr.v14i2.1 ↗
37. 10.2174/138920021766616072815293910.2174/1389200217666160728152939 ↗
38. 10.1016/j.ejpb.2015.03.01810.1016/j.ejpb.2015.03.018 ↗
39. 10.1080/21691401.2017.133702910.1080/21691401.2017.1337029 ↗
40. Cotter TG, Lennon SV, Glynn JG, et al. Cell death via apoptosis and its relationship to growth, development and differentiation of both tumour and normal cells. Anticancer Res. 1990;10:1153–1159.
41. 10.1002/cyto.99013080210.1002/cyto.990130802 ↗